Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – In terms of overall survival, carboplatin plus the oral fluoropyrimidine derivative S-1 is as effective as carboplatin plus paclitaxel in chemotherapy-naive patients with…
NEW YORK (Reuters Health) – Patients with papillary thyroid cancer who undergo lobectomy do as well as those who undergo total thyroidectomy, while external beam radiation is associated…
NEW YORK (Reuters Health) – The risk of second primary neoplasms (SPNs) of the central nervous system in survivors of childhood cancer increases greatly with the dose of…
NEW YORK (Reuters Health) – The off-label use of recombinant factor VIIa for hemostasis in patients without hemophilia confers only modest benefits but may increase the risk of…
NEW YORK (Reuters Health) – Compared with zoledronic acid, the monoclonal antibody denosumab is more effective in delaying skeletal-related events in women with breast cancer that has metastasized…
NEW YORK (Reuters Health) – The tyrosine kinase inhibitors gefitinib or erlotinib may slow the development of central nervous system metastases in patients with advanced non-small cell lung…
NEW YORK (Reuters Health) – Women with breast cancer treated with anthracycline-taxane based regimens are more likely to become amenorrheic than women treated with just anthracyclines or conventional…
NEW YORK (Reuters Health) – After first-line treatment with bevacizumab plus interferon-alpha2a, subsequent therapy with tyrosine kinase inhibitors (TKIs) improves survival in patients with metastatic renal cell carcinoma,…
NEW YORK (Reuters Health) – High-dose chemo followed by autologous stem-cell transplantation achieves good results in patients with relapsed Hodgkin’s lymphoma, and outcomes are not improved by additional…
NEW YORK (Reuters Health) – In order to minimize the risk of potential harms, erythropoiesis-stimulating agents (ESAs) in patients undergoing myelosuppressive chemotherapy should be administered at the lowest…
